Ask AI
Therapeutic Advancements in LS SCLC

CE / CME

Enhancing Outcomes in Limited-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Pharmacists: 0.25 contact hour (0.025 CEUs)

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: September 18, 2025

Expiration: March 17, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Kim S, Park H, Chiang A. Small cell lung cancer: a review. JAMA. 2025;333:1906-1917.
  2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. seer.cancer.gov/statistics-network/explorer/application.html. Accessed September 11, 2025
  3. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47-53.
  4. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111-1116.
  5. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476-484.
  6. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: small-cell lung cancer. v.1.2026. Accessed September 11, 2025.
  7. Blackhall F, Girard N, Livartowski A, et al. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study. BMJ Open. 2023;13:e052556.
  8. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391:1313-1327.
  9. Erciyestepe M, Ekinci ÖB, Doğan HGY, et al. Factors affecting survival and prognosis in extensive stage small cell lung cancer. BMC Pulm Med. 2025;25:160.
  10. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.
  11. Kalemkerian GP, Khurshid H, Ismaila N. Systemic therapy for small cell lung cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2025;43:101-105.
  12. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-271.
  13. Walls GM, Mistry H, Barlesi F, et al. Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: a brief report from the CONVERT trial. Int J Radiat Oncol Biol Phys. 2024;119:1386-1390.
  14. Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023;41:2394-2402.
  15. Gronberg BH, Aanerud M, Dumoulin DW, et al. Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). Presented at: 2025 American Society of Clinical Oncology; May 30 - June 3, 2025. Abstract LBA8005.
  16. Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024;12:799-809.
  17. Higgens K, Hu C, Ross HJ, et al. Concurrent chemoradiation ± atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG Oncology/Alliance LU005. Int J Radiat Oncol Biol Phys: ASTRO. 2024;120:S2.